March 2024

Marketing Material

Bionics

The AtonRâ Bionics is a long-only, USD-based, actively managed certificate.

Bionics, through the merger of biology and electronics, improves the quality and lifespan of the world population. The theme continues to benefit from long-term drivers, notably an ageing world population, a shortage of donated organs, and technological advancements.

Technology plays a significant role in healthcare, improving productivity, lowering healthcare costs and making human enhancement a reality.

The investment universe encompasses next-generation prosthetics, medical wearables and devices, surgical robots, exoskeletons, 3D printing, synthetic biology and artificial intelligence, all playing a major role in the emergence of bionics.

Main Features
Asset Class Equity
Legal Structure Actively Managed Certificate
Investment Index Long
Launch date 25-Jun-19
Currency USD
Type of Return Total return
Ticker JMLNARBN
isin XS1668108415
Issuer JP Morgan
Issue Price 150
Last Price 153.28
Sharpe Ratio 0.02
Correlation 0.67
Beta 1.35
Reference Index MSCI World Health Care Net (USD)
Liquidity Daily
# Holdings 20
Management Fees 1.30%
Issuer Fees 0.20%
Performance Fees 15.00%
ALL TIME HIGH ALL TIME LOW
PRICE: 269.8 PRICE: 114.0
DATE: 12-Feb-21 DATE: 30-Oct-23

Bionics

The AtonRâ Bionics is a long-only, USD-based, actively managed certificate.

Bionics, through the merger of biology and electronics, improves the quality and lifespan of the world population. The theme continues to benefit from long-term drivers, notably an ageing world population, a shortage of donated organs, and technological advancements.

Technology plays a significant role in healthcare, improving productivity, lowering healthcare costs and making human enhancement a reality.

The investment universe encompasses next-generation prosthetics, medical wearables and devices, surgical robots, exoskeletons, 3D printing, synthetic biology and artificial intelligence, all playing a major role in the emergence of bionics.

Monthly Returns $

(Net of fees)

* Estimated
* Actual

JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC ANNUAL
2024 -3.3% 0.0% 3.9% 0.5%
2023 3.0% -1.9% 1.1% 6.1% -0.7% 6.6% -2.2% -16.3% -11.4% -14.0% 18.3% 10.8% -6.1%
2022 -17.2% 3.3% 4.4% -18.2% -7.6% -3.1% 12.1% 7.5% -6.6% 9.6% 4.3% -6.7% -21.4%
2021 4.5% -4.4% -3.2% 8.4% -7.1% 9.0% -5.9% 4.8% -7.3% 5.0% -11.9% -2.1% -12.0%
2020 -0.2% -5.6% -7.1% 15.4% 7.8% -0.1% 10.4% 3.6% 3.3% -3.8% 10.5% 6.3% 45.3%
2019 1.1% -0.3% -0.8% -0.0% 1.1% 7.1% -0.3% 7.8%
Industry Exposure

Top 3 Holdings
  • SHOCKWAVE MEDICAL
  • DEXCOM
  • INSULET
Top 3 Contributors
  • SHOCKWAVE MEDICAL
  • DEXCOM
  • INSPIRE MEDICAL
Worst 3 Contributors
  • PACIFIC BIOSCIENCES
  • TRANSMEDICS GROUP
  • LANTHEUS
Geographical
Breakdown
Currency
Exposure
Asset
Allocation
Equity Market Cap
Distribution
Equity
Liquidity*

*On average 3 Months daily trading volume

Risk
Scale

6


The actual risk can vary significantly if you cash in at an early stage and you may get back less. You may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back

Industry Exposure